Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017) which is completed phase 2 clinical trial for the treatment of Alzheimer's disease and Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. In addition, it has an agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.